Navigation Links
ViroPharma Incorporated Reports Fourth Quarter and Full Year 2012 Financial Results
Date:2/27/2013

EXTON, Pa., Feb. 27, 2013 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) reported today its financial results for the fourth quarter and year ended December 31, 2012.

In 2012, we:

  • Achieved $428 million in annual net product sales, highlighted by $327 million in Worldwide net sales of Cinryze® (C1 esterase inhibitor [human]);
  • Generated net sales of approximately $17 million in Europe;
  • Attained GAAP net income of $6 million; and non-GAAP adjusted net income of $51 million;
  • Delivered positive cash flows from operations of $43 million;
  • Utilized $180 million of cash to repurchase approximately 7 million shares of ViroPharma stock; and
  • Finished the year with working capital of $339 million, including cash, cash equivalents and short-term investments of $247 million.
  • Net sales were $106.5 million and $427.9 million for the fourth quarter and year ended December 31, 2012, respectively, as compared to $145.6 million and $544.4 million in the comparative periods of 2011, respectively.  The decline in net sales quarter over quarter and year over year was driven as a result of the loss of Vancocin revenues partially offset by Cinryze growth. The 2012 U.S. Cinryze net sales of $320.6 million included approximately $311 million of patient demand.  The balance represented additional inventory in the channel. 

    "ViroPharma enters 2013 in a strong position to generate significant growth for years to come," stated Vincent Milano, ViroPharma's chief executive officer. "Cinryze in the U.S. continues to exceed our expectations, our products in Europe are beginning to demonstrate traction as we continue to expand those launches throughout the EU, the pipeline is more robust than it has ever been in our company's history and financially our company is in a very good position to remain opportun
    '/>"/>

    SOURCE ViroPharma Incorporated
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12

    Related medicine technology :

    1. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
    2. Faruqi & Faruqi, LLP Announces Investigation of ViroPharma Incorporated
    3. ViroPharma To Participate In The JMP Securities Healthcare Conference
    4. Berger & Montague, P.C. Reminds Viropharma Shareholders That The Deadline To Petition The Court To Act As Lead Plaintiff Is July 23, 2012
    5. ViroPharma To Release 2012 Second Quarter Financial Results On August 9, 2012
    6. ViroPharma Incorporated Reports Second Quarter 2012 Financial Results
    7. ViroPharma to Present at the Stifel Nicolaus 2012 Healthcare Conference
    8. ViroPharma To Host Analyst And Investor Seminar On September 21, 2012
    9. ViroPharma Incorporated Reports Third Quarter 2012 Financial Results
    10. ViroPharma Launches Novel Campaign to Illustrate the Emotional Burden of Hereditary Angioedema
    11. ViroPharma To Participate In Two Upcoming Healthcare Investor Conferences
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:6/1/2015)... CHICAGO, Ill. , June 1, 2015  AbbVie ... 2015 Healthcare Conference on Thursday, June 4, 2015. ... will participate in a question and answer session at ... webcast of the presentation will be accessible through AbbVie,s ... archived edition of the session will be available later ...
    (Date:6/1/2015)... BOSTON , June 1, 2015 Symbiotix ... a $2.3 million Phase 2 Small Business Technology Transfer ... (NIH) National Institute of Allergy and Infectious Diseases (NIAID). ... is developing a novel class of molecular therapeutics ... lead clinical candidate, Polysaccharide A (PSA), is the first ...
    (Date:6/1/2015)... N.J. , June 1, 2015  Elusys ... and Drug Administration (FDA) has accepted for filing ... Anthim® (obiltoxaximab) for the treatment and prevention of ... submitted on March 20, 2015. Anthim is a ... Stockpile, the U.S. government,s repository of critical medical ...
    Breaking Medicine Technology:Symbiotix Biotherapies Announces $2.3 Million Award from NIH's National Institute of Allergy and Infectious Diseases (NIAID) 2U.S. Food And Drug Administration Accepts Biologics License Application For Anthim (Obiltoxaximab) 2U.S. Food And Drug Administration Accepts Biologics License Application For Anthim (Obiltoxaximab) 3
    ... NEW YORK, April 18, 2012 Financial executives in ... excise tax and the burden of its related compliance ... bottom lines, according to a survey conducted by KPMG ... of respondents said their companies are already contemplating actions ...
    ... NEW YORK, April 18, 2012 ... initiates coverage on Pacira Pharmaceuticals ... price target $18.00. ... is a member of the ...
    Cached Medicine Technology:KPMG Survey: Medical Device Execs Say New Excise Tax Will Hit Their Company Bottom Lines Hard 2KPMG Survey: Medical Device Execs Say New Excise Tax Will Hit Their Company Bottom Lines Hard 3
    (Date:6/1/2015)... The National Association of Professional Women ... 2015-2016 inductee into its VIP Professional Woman of the ... for leadership in safety, environment, health and emergency response. ... professional women, boasting more than 700,000 members and over ... Lourinda with this important honor,” said NAPW President Star ...
    (Date:6/1/2015)... NY (PRWEB) June 02, 2015 ... Selma Tansey as a 2015-2016 inductee into ... recognized with this prestigious distinction for leadership in mental ... for professional women, boasting more than 700,000 members and ... present Selma with this important honor," said NAPW President ...
    (Date:6/1/2015)... Austin, TX (PRWEB) June 01, 2015 ... LLC, to facilitate their investors IRA transactions. AdvantaIRA Trust, ... , Giving investors the ability to fund positions using ... choice to participate on a project, even if there ... 2. Provide an additional funding source for Carson and ...
    (Date:6/1/2015)... Unlike most generator rental companies, which raise their rates by ... when the generator is in standby mode, WPP charges a ... or not. WPP also offers an offsite storage option — ... few hours — for companies that do not have the ... “Even minor business disruptions are very expensive for commercial and ...
    (Date:6/1/2015)... Linda Kincaid, age 67, knew something was wrong. She constantly ... thought it was just a part of getting older, but ... After going to the doctor, she received a distressing diagnosis: ... might happen to her. , Linda is not alone. As ... each year. Valve disease involves damage to one or more ...
    Breaking Medicine News(10 mins):Health News:National Association of Professional Women Inducts Lourinda Willey, Owner and Principal of Lourinda R. Willey LLC, Into its VIP Professional Woman of the Year Circle 2Health News:NAPW Inducts Selma Tansey, Executive Director of Washington Communities Human Services, Into its VIP Professional Woman of the Year Circle 2Health News:Carson Energy Brings Oil Wells To IRAs 2Health News:Worldwide Power Products Offers “Budget Billing” Contingency Generator Rental Program; Guarantees Power for Peak of Hurricane Season and Beyond 2Health News:A New Online Resource for Those Living with Heart Valve Disease 2Health News:A New Online Resource for Those Living with Heart Valve Disease 3
    ... The chief executive officer of a health authority in St. ... faulty tests that may have affected the care of ... the Eastern Health Regional Authority agreed that Eastern Health could ... knew about the hormone receptor tests. ,'I regret ...
    ... agreed on a $5-billion initiative with major banks to retrofit ... first such enterprise to combat climate change. ,Former ... week with a summit in New York attended by mayors ... discuss climate change. ,Clinton's initiative launched on Wednesday ...
    ... President A.P.J. Abdul Kalam Thursday stressed on the necessity ... to increase neuro activities of mentally challenged people. ... of Manovikas Kendra, a premier rehabilitation and research institute ... going on worldwide and it will take five to ...
    ... offered their first insights at research on a group ... will serve as models of typical childhood development. ... Health study suggest that healthy children perform better on ... was particularly true among children from low-income families. ...
    ... found that chemical relaxers used to straighten hair are not ... among African-American women. ,Hair relaxers can enter the ... are not fully monitored by the Food and Drug Administration, ... study named Black Womens Health Study was conducted by a ...
    ... In order to makeup for the loss of the ... hospitals run by state governments , the railways and ... from them to make them profit making units. ... Hindustan Antibiotics Limited, Bengal Chemicals and Pharmaceuticals Limited, Hindustan ...
    Cached Medicine News:Health News:Faulty Hormone Tests Compromised Healthcare Of Breast Cancer Patients 2Health News:World Cities Join Hands to Combat Climate Change 2Health News:Library Of Brains To Aid Study of Brain Development In Children 2Health News:Library Of Brains To Aid Study of Brain Development In Children 3Health News:Hair Relaxers Not Linked With Breast Cancer Risk 2Health News:Government Hospitals to the Rescue of Loss-making Pharma Companies 2
    ... SP Surgical Table combines innovation and design ... up to 1,000 lbs. You can safely ... normal and reverse orientation and have virtually ... patients.,The Amsco 3085 SP Table offers the ...
    ... 1st MPJ IMPLANT SYSTEM is a unique ... of the 1st metatarsal phalangeal joint resulting ... revision of a previous arthroplasty. The ... pain relief, superior function and longevity. ...
    ... part in our daily lives. But degenerative ... cause severe handicaps. A decisive consideration in ... to produce a reconstructed joint function that ... possible.,The cementless RM Finger System has proven ...
    ... important part in our daily lives. But ... can cause severe handicaps. A decisive consideration ... was to produce a reconstructed joint function ... nearly possible.,The cementless RM Finger System has ...
    Medicine Products: